Conclusion
Our data demonstrates that high SLN detection rates can be achieved by gynecologic oncologists treating women with endometrial cancer at non-specialty surgical institutions. Optimization of provider technique and expertise is critical in order to meet defined standards of SLN detection accuracy. Once individual surgeons demonstrate proficiency in SLN mapping and detection, based on our data, it would seem reasonable to recommend SLN mapping and biopsy as standard of care for the treatment and management of uterine endometrial cancer across all institutions.
Declarations:
The authors have no financial, personal, political, intellectual or religious interests to disclose.
Contribution to authorship:
Sarah Werner is the main investigator- including planning and compiling data and writing abstract and manuscript. Therese Gadomski provided assistance with project planning, data collection and manuscript editing. Drs. Pereira and Villella are the primary investigators for this project and are involved in conception, planning and manuscript editing. Tung Ming Leung contributed with data analysis.
Ethics: IRB approval for this retrospective analysis did not include approval from ethics committee.
Funding: Authors have no external funding to disclose for the completion of this project.
References
  1. R.L Siegal, K.D Miller, A. Jermal. Cancer Statistics, 2020. CA Cancer J Clin. 77 (2020) 7-30.
  2. Smith Anna J, Fader Amanda, Tanner Edward. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. American Journal Obstetrics and Gynecology 2017; 459-476
  3. NCCN, Guidelines Version 1.2014, Endometrial Carcinoma, 2014 (Accessed April 4, 2020).
  4. Society of Gynecologic Oncology. (2015) Clinical Practice Statement: The Role of Sentinel Lymph Node Mapping in Endometrial Cancer. Chicago, IL. 5. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol. 2005; 23: 7703-7720
  5. Kang, S., Yoo, H. J., Hwang, J. H., Lim, M., Seo, S., & Park, S. (2011). Sentinel lymph node biopsy in endometrial cancer: Meta-analysis of 26 studies. Gynecologic Oncology,123 (3), 522-527. doi:10.1016/j.ygyno.2011.08.034
  6. Khoury-Collado F, Glaser GE, Zivanovic O, et al. Improving sentinel lymph node detection rates in endometrial cancer: How many cases are needed? Gynecol. Oncol. 2009; 115: 453-455.
  7. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol. 2005; 23: 7703-7720.
  8. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl. Cancer Inst. 2008; 100: 1707-1716.
  9. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 2009; 373: 125-136.
  10. Holloway R, Gupta S, Stavitzski N et al. Sentinel lymph node mapping with stagging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol. Oncol. 2016; 141: 206-210
  11. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl. Cancer Inst. 2008; 100: 1707-1716.
  12. How J, Gauthier C, Abitbol J, et al. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecol. Oncol. 2017; 144: 503-509.
  13. Dowdy SC, Mariani A. Lymphadenectomy in endometrial cancer: when, not if. Lancet 2010; 375: 1138-1140.
  14. Tanner EJ, Sinno AK, Stone RL, et al. Factors associated with sucessful bilateral lymph node mapping in endometrial cancer. Gynecol. Oncol. 2015; 138: 542-547